Novel Mira W Pdf
Olivie Inoue
Lee sat down with me in a cafe about a mile from the Cambridge, Massachusetts, home she shares with her husband and sons to discuss mental illness, multiculturalism, and the creative evolution of Everything Here Is Beautiful.
ELEANOR J. BADER: Lucia, the younger sister in Everything Here Is Beautiful, suffers from schizoaffective disorder, and the novel tracks her many psychotic breaks with compassion, terrifying realism, and multilayered complexity. Did you know about this disorder from personal experience?
There was another issue I wanted to highlight, as well. Fairly early on I made a decision not to make the characters white. I have yet to see a story of mental illness that does not involve white, middle-class people, so I decided to create one. I wanted to show that the disease impacts diverse racial and ethnic communities. In addition, since most accounts focus on the onset of the disease in young adults, I wanted to show that schizoaffective disorder occurs in people of all ages.
Immigration, both legal and not, is a theme throughout the book, and readers see this issue from several angles. Yonah and Manuel are newcomers to the United States and Lucia is an American in Ecuador. Did you anticipate this being such a timely issue?
No. I developed the characters a long time ago and had no idea what the political climate would be like when the book was published. I certainly hope readers will view the struggles the characters go through with empathy and compassion.
I started writing Everything Here Is Beautiful in 2013 and did four drafts in two and a half years. Once I got an agent and the book was sold, the editors at Viking asked for revisions, which I spent a year on.
I want readers to understand the complexity of taking care of someone with a mental illness and see that mental illnesses occur in nonwhite populations. I also hope the book reaches people who might not read a memoir, news story, or blog post about mental illness and break through the shame, stigma, and silence that persist in many cultures when someone suffers from a psychological disorder.
LARB publishes daily without a paywall as part of our mission to make rigorous, incisive, and engaging writing on every aspect of literature, culture, and the arts freely accessible to the public. Help us continue this work with your tax-deductible donation today!
Readers know from the beginning that everyone is gone, assumed dead, that the documentary is showed once on the Imagine Network and speculates what happened to everyone based on the footage captured of mermaids swamping the ship. Transcripts of the documentary are shared throughout the novella, adding a fun multi-media effect.
I first heard about this novel on the Books in the Freezer podcast. As the two hosts were describing it, I thought: A book about violent creatures of the sea that are rumored to be mermaids? Sign me up!
One of the elements that I wanted to mention right off the bat was how diverse this cast was. It was really neat to see how perfectly the author developed the characters and how their differences were made apparent to both the reader and their fellow cast members.
And my goodness, this cast! I adored a number of them so much! A number of times, I talked to my husband about how nervous I was that they were going to be killed. A few characters were a bit rough around the edges, while other characters made my skin crawl or made my blood boil. But each of them were so interesting.
The story focused mainly on the same handful of characters, but also turned to focus on other supporting characters as the story progressed to really give the reader the full scope of things. I really enjoyed this format because it moved along much more fluidly than books that have chapters dedicated to each of the varying perspectives. The sections in this story that were from the perspective of the dolphins and sea creatures were especially interesting and also quite emotional!
It was also refreshing to see one scene where they stole a quick kiss before moving on with their tasks that was so refreshing! Far too often you see these long drawn out, totally unnecessary make out sessions, where the reader sits there thinking something bad is going to happen simply because they are wasting time. These two were too smart to waste time.
This book is one of those rare finds that is just so wonderfully written and perfectly horrific that I want to shout about it from the rooftops to make sure horror fans go out and snag a copy immediately.
I absolutely love this review! This one is on my wishlist so I am so happy to see you enjoyed it so much. And yay for a brilliant diverse cast as well. It sounds like the pacing and atmosphere are brilliant ^.^
The writer side of me was intrigued by your choices in narrators and points of view. We get chapters from Miranda, Lucia, Manny, and Yonah, in both third- and first-person voices, sometimes back-to-back. In addition, a few chapters are told in an omniscient point of view of a particular setting, such as a psychiatric ward and a Minnesota town. Was it difficult to go back and forth in this way, and how did you decide what chapters to tell in which POV?
Me, too! I think the guilt is due to my feeling like I should be writing, not reading (which is so pleasurable). Speaking of which, have you started writing your next novel? If so, can you tell us anything about it?
Lucia said she was going to marry a one-armed Russian Jew. It came as a shock, this news, as I had met him only once before, briefly, when I was in town for a meeting with a pair of squat but handsome attorneys. His name was Yonah. He owned a health food store in the East Village, down the street from a tattoo parlor, across from City Video, next door to a Polish diner, beneath three floors of apartments that Lucia said he rented out to the yuppies who would soon take over the neighborhood. He had offered me tea, and I took peppermint green, and he scurried around, mashing Swiss chard and kale in a loud, industrial blender, barking orders to his nephews, or maybe they were second or third cousins (I never knew, there were so many), because they were sluggish in their work of unloading organic produce off the delivery trucks. He yelled often. I thought, This Yonah is quite a rough man.
We would like to collect information during your visit to help us better understand site use. This data is anonymized, and will not be used for marketing purposes. Read More on our Privacy Policy page. You can withdraw permission at any time or update your privacy settings here. Please choose below to continue.
MIRA-55 is under investigation for treating adult patients suffering from neuropathic pain as well as anxiety and cognitive decline often associated with early-stage dementia. Unlike THC (the principal psychoactive compound in marijuana), which can impair cognitive function, MIRA-55 has demonstrated in pre-clinical studies that it can improve memory by 100% in wild-type mice.
"We are thrilled with the DEA's decision, which underscores the potential of MIRA-55 as a groundbreaking therapeutic candidate," said Erez Aminov, Chairman & CEO of MIRA Pharmaceuticals. "This ruling allows us to focus on MIRA-55's unique cognitive and anxiety benefits. With access to $90B traditional neurological and $30B cannabis markets, MIRA-55 represents a significant value proposition for our company. We remain committed to advancing it through the development pipeline for treating these diseases from which so many currently suffer."
"Anxiety disorders affect around 40 million U.S. adults, causing excessive apprehension, worry, fear, nervousness, physical symptoms like sweating, shortness of breath, and palpitations," said Dr. Itzchak Angel, Chief Scientific Advisor of MIRA Pharmaceuticals. "Current treatments such as SSRIs and SNRIs can take weeks to work and are associated with side effects. Cognitive impairment, affecting 16 million people (about the population of New York) in the U.S., similarly lacks effective treatments. MIRA-55 offers a promising alternative with the potential for quicker relief and fewer side effects for both anxiety and cognitive impairment."
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian and Mexican rights for Ketamir-2, a novel, patent pending oral ketamine analog under investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation and post-traumatic stress disorder. The U.S. Drug Enforcement Administration's scientific review of Ketamir-2 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations.
In addition, MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from neuropathic pain as well as anxiety and cognitive decline, often associated with early-stage dementia. MIRA-55, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders. The U.S. Drug Enforcement Administration's scientific review of MIRA-55 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act and its governing regulations.
This press release and the statements of the Company's management related thereto contains "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "Aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding MIRA-55's potential in treating certain mental health conditions or neuropathic pain and statements regarding the timing for the Company's preclinical studies and the filing of an IND for MIRA-55. Any forward-looking statements in this press release are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results (including the anticipated benefits of MIRA-55 and the pre-clinical and clinical pathway for MIRA-55 as discussed herein) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at -filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
c80f0f1006